Chapter 18: Cholinesterase Inhibitors and Their Use in Myasthenia Gravis

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Usually when we look at how a drug works in the body, it's a pretty straightforward game of mimicry, right?

Like we give a medication, it acts almost exactly like a natural chemical messenger to a receptor, and we get a predictable result.

It's clean.

Yeah, it's the classic direct agonist approach.

The drug just impersonates the body's own signals to turn a system on.

But then you encounter drugs that just flip that entire clean mechanism completely on its head.

So welcome to today's Deep Dive.

We are talking directly to you, the nursing student who is currently gearing up to conquer pharmacology.

Your mission today.

Exactly.

Your mission, and ours, is to master Chapter 18 of Lane's Pharmacology for Nursing Care.

We're doing a deep dive into cholinesterase inhibitors and their primary use in treating myasthenia gravis.

And the reason the biology here is so incredibly fascinating is that these drugs don't mimic the body's messengers at all.

No, not even a little bit.

Right.

Instead, they act like a wrench deliberately thrown into the body's molecular cleanup crew.

Yeah, what we're really analyzing here are indirect -acting cholinergic agonists.

And to understand why we call them indirect, you really have to look at the anatomy of how the nervous system resets itself.

After sending a signal, you mean?

Right.

So imagine a nerve firing.

It releases the neurotransmitter acetylcholine into the synaptic gap to deliver its message to a receptor.

But once that message is delivered, an enzyme called acetylcholinesterase immediately sweeps into that gap and just shreds the acetylcholine.

It clears the synapse so the system is ready to fire again.

Exactly.

It's the molecular cleanup crew.

So that enzyme is the target.

And these drugs, the cholinesterase inhibitors, they specifically target that enzyme, totally ignoring the actual receptor.

They do.

By binding to the acetylcholinesterase, they prevent the degradation of the acetylcholine.

So the drug itself never even touches the patient's actual receptors.

It simply stops the cleanup process.

Because they block the enzyme from doing its job, the acetylcholine isn't getting broken down.

It just builds up in the junction.

Yeah, it keeps pooling in that space, which results in a massively enhanced cholinergic action at all the cholinergic junctions throughout the whole body.

That means muscarinic, ganglionic, and neuromuscular receptors are all just being hit with these sustained signals.

Which tells us we're going to see a massive broad spectrum response.

Which is useful, sure, but potentially very dangerous if you don't know exactly what to look for.

Oh, absolutely.

So we're going to translate all this dense chemistry into the practical cause and effect, clinical reasoning you need for exams and your actual bedside practice.

And I think a great place to start is looking at the two major categories these drugs fall into, the reversible and irreversible inhibitors.

Yeah, when you look at table 18 .1 for the reversible inhibitors, the ones that have a moderate duration of action, you'll notice their therapeutic applications are incredibly narrow.

Because they lack selectivity, right?

They just boost acetylcholine everywhere.

Exactly.

So we really only use them for a few heavy hitting conditions.

Right.

You definitely aren't prescribing these for a mild headache.

We're talking about using them for myasthenia gravis, or MG,

treating glaucoma, managing Alzheimer's and Parkinson's dementia, reversing competitive non -depolarizing neuromuscular blockade after surgery.

That's a mouthful.

It really is.

And acting as an antidote for patients poisoned by muscarinic antagonists.

So to understand how one type of drug does all of that, we have to look at the prototype drug for the reversible category, which is pyridostigmine.

And pyridostigmine is the absolute drug of choice for managing myasthenia gravis.

But the chemical structure of pyridostigmine is what dictates everything a nurse needs to know about handling it.

It contains a quaternary nitrogen atom.

Okay.

I want to pause on that, because whenever I see quaternary nitrogen atom in a text, I know it means the molecule always carries a positive charge.

Like, it's highly polar.

Yes, very polar.

And a lot of times we visualize that as the drug carrying a physical heavyweight.

But it's actually about solubility, right?

Our cellular membranes, like the GI tract, the blood -brain barrier, the placenta, they're all made of lipids.

They're fat -based.

And water and oil just don't mix.

Exactly.

A highly charged polar molecule like pyridostigmine is basically water soluble.

So trying to push it through a fat -based lipid membrane is like, I don't know, trying to push a strong magnet through a solid sheet of rubber.

It just bounces off.

It's like a hiker wearing a massive backpack trying to squeeze through a fence.

I love that analogy.

It can't easily cross those barriers.

And that polarity has massive cause and effect implications for clinical practice.

Because it just gets repelled.

Right.

Because it gets repelled by those lipid membranes, pyridostigmine is absorbed very poorly when a patient takes it orally.

The body just can't pull it across the GI tract efficiently at all.

But and this is cool, that same lack of absorption is also its greatest safety feature, isn't it?

Since it gets rejected by lipid barriers, it can't cross the blood -brain barrier or the placenta.

Yeah.

We sacrifice easy oral absorption to keep the central nervous system and a developing fetus perfectly safe.

It's really an elegant trade -off.

I love when the underlying chemistry makes the clinical outcome so obvious like that.

Yeah.

So how does pyridostigmine actually fight the enzyme?

The text calls it a hydrolysis reaction.

Let's visualize that process.

Okay.

So under normal healthy conditions, cholinesterase breaks down acetylcholine into choline and acetic acid using a water molecule.

That's the literal definition of hydrolysis.

Right.

And this enzymatic reaction is unbelievably fast.

I mean, a single molecule of the enzyme can shred a huge amount of acetylcholine in a fraction of a second.

It bites down, splits the transmitter, and is instantly ready for the next one.

But then pyridostigmine enters the synapse and acts like a molecular decoy.

Yes.

The chemical reaction between pyridostigmine and the enzyme is very similar to the natural reaction but with one massive difference.

The enzyme splits pyridostigmine very, very slowly.

Oh, so it just gets stuck.

Basically, yeah.

Once the drug binds to the enzyme, the enzyme gets its teeth stuck.

While it's struggling to degrade the drug, it is completely unavailable to break down the body's actual acetylcholine.

Which means the acetylcholine just accumulates and constantly activates the cholinergic receptors?

Yeah.

But what are the physical pharmacologic effects of that buildup on the patient?

The text says it's entirely dose dependent.

It is.

At therapeutic doses, you'll mostly see effects on muscarinic receptors on the internal organs and nicotinic receptors at the neuromuscular junction.

So the muscarinic effects would mimic a parasympathetic overdrive, the classic rest and digest system.

Right.

So a buildup of acetylcholine there triggers bradycardia, dropping the heart rate.

You see bronchial constriction in the lungs, urinary urgency,

massively increased glandular secretions, increased GI tone and motility.

Emeiosis, right.

Constriction of the pupils.

Exactly.

That makes intuitive sense.

You're juicing the rest and digest pathways.

But the neuromuscular effects are where I get a bit tripped up.

The text explains that at normal therapeutic doses,

these drugs increase the force of muscle contraction.

Yes, they do.

But at toxic doses, they actually reduce the force of contraction.

Wait, I'm confused.

If the drug's whole job is to increase muscle contraction by pooling acetylcholine, how does giving too much of it cause paralysis?

Wouldn't it just make the muscle contract harder and faster?

It feels completely counterintuitive until you look at how a muscle actually resets.

For a muscle to contract a second time, the motor end plate has to repolarize.

The electrical charge has to clear.

OK.

So if there's a massive toxic flood of acetylcholine sitting in that neuromuscular junction, the receptors are forced to stay open.

The motor end plate is kept in a state of constant depolarization.

Oh.

So the muscle never gets a fraction of a second to reset its electrical charge.

And if it can't reset, it physically cannot fire again.

It just freezes.

It freezes in a depolarized state.

That's called a depolarizing neuromuscular blockade.

The muscle is literally paralyzed by overstimulation.

That is a brilliant mechanism to understand.

So let's take these effects and look at their clinical uses and adverse effects.

We know period of Sigmund is the main therapy for myasthenia gravis, which we'll get into deeply in a few minutes.

It's also used to reverse competitive non -depolarizing neuromuscular blockers post -surgery.

So if a patient was paralyzed with pancoronium for an operation, giving para to stigmund allows enough acetylcholine to build up that it physically kicks the pancoronium off the receptors.

Waking the muscles back up exactly and knowing that mechanism tells you exactly what the adverse effects will be.

Excessive acetylcholine buildup guarantees excessive muscarinic stimulation.

So the patient is going to be sweating profusely, salivating, experiencing severe stomach cramps, diarrhea, and intense urinary urgency.

Which allows a nurse to logically deduce the critical contraindications.

You would never administer this to a patient who has an obstruction of the gastrointestinal or urinary tract.

Because if the physical pipes are blocked,

you don't want to chemically stimulate the body to push harder and harder against that blockage.

You could cause a rupture.

Exactly.

You also need to exercise extreme caution or avoid these entirely in patients with peptic ulcer disease, asthma because of that severe bronchial constriction we mentioned, and bradycardia since the drug will slow their heart rate down even further.

Okay, let's talk about the major drug interactions because this is where safety protocols are made or broken.

First, muscarinic antagonists.

Atropine is the classic example here.

It does the exact opposite of our cholinesterase inhibitors.

Making atropine the perfect direct antidote.

If a patient is experiencing excessive muscarinic stimulation from a cholinesterase inhibitor, an injection of atropine blocks those receptors and stops the overwhelming symptoms.

And it works the other way too, right?

Yeah.

Conversely, if someone is poisoned by atropine, administering a cholinesterase inhibitor can force enough acetylcholine into the gap to overcome that blockade.

But the interaction with neuromuscular blockers is where clinical reasoning is vital.

We just said these drugs reverse non -depolarizing blockers like pancoronium.

But what if the anesthesiologists use succinylcholine instead?

Oof, that distinction can be life or death.

Succinylcholine is the depolarizing neuromuscular blocker.

It works by keeping the muscle depolarized, very similar to the toxic effect of our inhibitors.

So if a patient has succinylcholine in their system, getting a cholinesterase inhibitor is completely contraindicated.

Because the cholinesterase inhibitor doesn't just stop the breakdown of acetylcholine, it also stops the breakdown of the succinylcholine itself.

So instead of reversing the paralysis, you are trapping the succinylcholine in the junction.

You intensify it.

You are effectively locking the patient into a paralyzed state for a prolonged period.

That's terrifying.

Okay, so we've built this robust picture of our prototype, pyridostigmine, being locked out of the brain because of its positive charge.

We also have another drug, neostigmine, which is very similar.

But looking at table 18 .3, it's typically administered via injection based on patient weight.

Right.

Phi, V, IM, or sub -Q mostly to reverse post -op blockade in the hospital.

Whereas pyridostigmine comes in, immediate and extended release oral tablets for patients managing their disease at home.

But what happens if a patient overdoses on a drug that is affecting their central nervous system?

Say someone is poisoned by an antihistamine and is delirious.

How do we cross that blood -brain barrier if our prototype just bounces off?

That is where phasostigmine comes into play.

Phasostigmine is the structural exception to the rule.

It's not a quaternary ammonium compound.

It does not carry that positive electrical charge.

It doesn't have the heavy backpack.

So it isn't completely water soluble.

It can dissolve into lipids.

Exactly.

Because it lacks that charge, it crosses those fat -based cellular membranes with absolute ease.

It easily enters the central nervous system.

Making phasostigmine the drug of choice for treating poisoning by atropine and other central muscarinic blockers.

It causes acetylcholine to build up in the brain, which then outcompetes the poison for the receptors, waking the patient up.

Spot on.

But while we are using these drugs to treat toxicities, we also have to be intensely aware of acute toxicity from the cholinesterase inhibitors themselves.

If a patient overdoses on these reversible inhibitors, they go into a life -threatening state called a cholinergic crisis.

And a cholinergic crisis is characterized by severe respiratory depression.

This happens partly because the central nervous system gets depressed, but primarily because of that depolarizing neuromuscular blockade we discussed.

Muscles of respiration just completely freeze.

They do.

And because it's a depolarizing blockade, you can't just give a drug to magically restart the muscles.

The treatment involves pushing IV atropine to halt the massive muscarinic symptoms, the secretions, and the bradycardia.

But you also have to put the patient on mechanical ventilation.

Right.

You literally have to breathe for them until the inhibitor wears off and the enzyme is free again.

Which naturally brings up a terrifying clinical question.

Reversible inhibitors eventually let go of the enzyme.

But what happens if a drug is specifically engineered to hold on forever?

Ah, yeah.

We are talking about the irreversible inhibitors, the organophosphates.

These molecules contain an atom of phosphorus and, unlike our positively charged reversible drugs, almost all organophosphates are highly lipid soluble.

They have no charge holding them back whatsoever.

None.

They absorb instantly from all routes.

They can pass directly through intact skin.

They have unrestricted access to every tissue, every organ, and the entire brain.

So what are they even used for?

If they absorb through the skin and permanently shut down the cleanup enzyme, they sound like weapons.

Therapeutically, their use is almost nonexistent.

There is only one clinical indication.

A drug called echothiophate, which is used as a topical eye drop for severe glaucoma.

Just one.

Just one.

Beyond that, because of their extreme toxicity, they are primarily manufactured as agricultural insecticides.

And historically, their main development was for military nerve agents.

Wow.

The mechanism is identical to pyridostigmine, right?

They bind to the active center of the colonist race enzyme, but the chemical bond they form is so aggressive that it's considered permanent.

Yes.

The toxic effects just persist until the patient's body can physically synthesize a brand new enzyme molecules, which takes days or weeks.

So if a farmer accidentally spills an organophosphate insecticide on their arm, what does that clinical presentation look like?

It looks like a catastrophic systemic cholinergic crisis.

And the textbook provides two crucial mnemonics to help nurses rapidly identify this state.

The first is SLUGE and the killer bees.

Let's walk through those, because visualizing this helps cement the pharmacology.

S is for salivation.

The patient will be profusely drooling.

L is for lacrimation.

Their eyes are uncontrollably tearing up.

U is for urination.

They lose bladder control.

D is for diaphoresis and diarrhea drenched in sweat, losing bowel control.

G is for gastrointestinal cramping, which is excruciating.

And E is for emesis, violent vomiting.

And then you have the killer bees, bradycardia, dropping the heart rate, bronchospasm, constricting the airways, and bronchorea, which means they're producing so much fluid in their lungs they are effectively drowning in their own secretions.

The alternative mnemonic is DUMBELS, which covers the exact same catastrophic parasympathetic overdrive.

You've got diaphoresis, diarrhea, urination, meiosis, the pinpoint pupils, the killer bees, emesis, lacrimation, and salivation.

But as horrifying as all those fluids and cramps are, the secretions aren't usually what kills the patient.

It's the nicotinic effects, right, at the neuromuscular junction.

Exactly.

The initial muscle twitching rapidly gets way to that depolarizing blockade.

The respiratory muscles freeze, and the text is blunt.

Death comes from apnea.

They suffocate.

So treatment must be rapid and aggressive.

You administer atropine immediately to dry up those SLDGE symptoms and open the airways.

You push diazepam to suppress the violent seizures caused by brain toxicity.

And you initiate mechanical ventilation with oxygen immediately.

Yes.

But for organophosphates, specifically, there is a specialized antidote called pralidoxum.

Wait, does pralidoxum just act like chemical scissors?

Does it just cut the permanent bond between the poison and the enzyme?

It does uncouple the organophosphate from the enzyme, particularly at the neuromuscular junction, but there is a massive terrifying catch.

It is a strict race against time.

If too much time passes between the exposure and the administration of pralidoxum, a chemical process called aging occurs.

Aging.

Let's dive into that because that sounds ominous.

Aging is a secondary chemical reaction where the bond between the organophosphate and the cholinesterase enzyme hardens.

It increases in strength until it is truly permanently unbreakable.

Think of it like wet cement.

Oh, man.

Pralidoxum can wash the cement away while it's wet, but once aging happens, the cement is fully cured.

Pralidoxum becomes completely useless.

And that aging timeline depends entirely on the specific poison.

The text notes that for a military nerve agent like Soman, aging occurs in just two minutes.

Two minutes to get an antidote.

Unbelievably fast.

For another agent called Tabun, it takes about 13 hours.

That is an intense clock for an emergency room nurse to be racing around.

It really is.

Let's shift gears from chemical warfare back to chronic patient care.

I want to look at the people who rely on these drugs every single day, patients with myasthenia gravis.

Right.

Myasthenia gravis is a severe neuromuscular disorder.

It's characterized by fluctuating muscle weakness and a rapid predisposition to fatigue.

In an assessment, you'll commonly see itosis, which is a pronounced drooping of the eyelids,

severe difficulty swallowing, and profound weakness of the skeletal muscles that worsens as the day goes on.

The pathophysiology driving this is an autoimmune process, right?

The patient's own immune system produces antibodies that hunt down and destroy the nicotinic am receptors on the skeletal muscle.

Yeah.

The text states that 70 % to 90 % of those functional receptors at the neuromuscular junction are just wiped out.

Wow.

So even if the nerve is perfectly healthy and releases a normal amount of acetylcholine, there simply aren't enough receptors left on the muscle side to catch the signal and trigger a contraction.

Exactly.

That is why a reversible cholinesterase inhibitor like pyridostigmine is the absolute cornerstone of their treatment.

But it's vital to clarify the therapeutic goal here.

This is not a cure.

No, not at all.

The pyridostigmine does nothing to stop the autoimmune attack, and it cannot regrow those lost receptors.

It merely prevents the breakdown of whatever acetylcholine the nerve releases.

It floods the junction, ensuring that the few surviving receptors are constantly bombarded with transmitter.

Maximizing whatever muscle strength the patient has left.

It's a lifelong symptom management strategy.

And when a nurse is managing a lifelong treatment, they have to consider the lifespan of the patient.

The person -centered care guidelines in the text provide some critical parameters.

Right.

Like if a patient with MG becomes pregnant, oral pyridostigmine is still recommended and considered safe.

But you absolutely cannot use intravenous pyridostigmine because the sudden spike in cholinergic activity can trigger premature uterine contractions.

Good point.

Also, neonates born to these patients might inherit some of those maternal antibodies and present with a transient, temporary form of neonatal MG that requires close monitoring.

And breastfeeding safety isn't definitively established,

though there are no specific alternative precautions for older adults just based on age.

Managing this disease really requires intense nursing vigilance, which brings us to the clinical applications you'll use on the floor.

There is one nursing action that takes priority over almost everything else when you're preparing to administer these oral medications.

The swallow test.

If a patient with MG is admitted to the hospital, their muscle strength might be so severely compromised that their swallowing reflex is gone.

You cannot simply hand them a pill and a cup of water and walk away.

Absolutely not.

The text explicitly directs you to assess their ability to swallow by giving them a few tiny sips of water before you give the oral medication.

If they choke, or if they simply cannot swallow the water, handing them a pill is an enormous aspiration risk.

You must alert the provider and switch to parental administration.

Another major implication is empowering the patient to take control of their own dosing.

Because MG symptoms fluctuate wildly based on stress, illness, and activity, finding the optimal dose is a constantly moving target.

So patients have to be taught to keep a detailed log.

Yes.

They track their drug administration times, the periods when they feel the most fatigued, their muscle strength before and after the dose, and any signs of excessive muscarinic stimulation like extra sweating or diarrhea.

They are actually taught to self -adjust their doses based on their anticipated exertion.

If a patient knows they are going grocery shopping or sitting down for a large, difficult -to -chew meal, they learn to take their medication 30 to 60 minutes beforehand.

Ensuring the drug's effect peaks exactly when they need the muscle strength the most.

But the most significant clinical puzzle a nurse will face with MG is distinguishing between two life -threatening crises that look almost exactly the same to an untrained eye.

Oh, this is crucial.

Imagine a patient with known myasthenia gravis is rushed into the emergency department.

They are profoundly weak, totally paralyzed, and struggling to breathe.

As the nurse, you have to immediately figure out, is this a myasthenic crisis or a cholinergic crisis?

Let's define the difference.

Because treating the wrong one will kill the patient.

A myasthenic crisis means the patient is under -medicated.

Their disease has aggressively progressed, or they missed several doses.

And there's nowhere near enough acetylcholine at the junction.

They are paralyzed by their underlying disease.

Whereas a cholinergic crisis means they are over -medicated.

They took way too much of their puridostigmine.

The acetylcholine is built up to massive toxic levels, and they are locked in that depolarizing neuromuscular blockade.

They are paralyzed by the cure.

Exactly.

Both patients are laying there paralyzed and suffocating.

But the treatments are polar opposites.

If it's a myasthenic crisis, you treat it by giving them more cholinesterase inhibitor, like a fast -acting dose of neostigmine.

But if it's a cholinergic crisis, pushing more inhibitor will throw more fuel on the fire and likely kill them.

You have to withhold all cholinesterase inhibitors and push atropine.

So how do you tell the difference?

The text provides a straightforward clinical decision tool based on our previous pathophysiology.

You look for the muscarinic signs.

You look for SLBGE.

If the patient is paralyzed, but they are also sweating profusely, drooling saliva, and their pupils are pinned tight,

that is a cholinergic crisis.

The muscarinic receptors are screaming, treat with atropine.

But if those excessive muscarinic signs are entirely absent, their skin is dry, their pupils are normal, then it is a myasthenic crisis.

Treat with neostigmine.

However, sometimes the clinical picture is murky.

The history is unclear.

The signs aren't definitive.

In those cases, the provider might elect to perform the edryphonium test.

Edryphonium is a cholinesterase inhibitor, but it is ultra -short acting.

The provider administers a tiny, challenging dose.

Wait, so if a patient might already be suffocating from too much acetylcholine, we inject them with a drug that makes more acetylcholine?

That sounds incredibly dangerous.

Why would we do that?

It is dangerous, which is why the ultra -short duration of edryphonium is critical.

It affects peak and vanish in minutes.

If you give that tiny dose and the patient suddenly gets stronger and can open their eyes, you instantly know the crisis was myasthenic.

They desperately needed more acetylcholine, and the edryphonium provided a temporary diagnostic boost.

But if you push the edryphonium and the patient immediately gets worse, their breathing becomes even more shallow, and their paralysis deepens, you just proved it was a cholinergic crisis.

You added fuel to the fire.

Because the drug wears off so rapidly, the added danger is brief.

But this leads to a critical nursing warning.

If a provider is performing the edryphonium test, you must have atropine and oxygen physically drawn up and directly in your hands.

Right.

If it is a cholinergic crisis, that tiny test dose could push their respiratory muscles into complete failure in seconds.

Exactly.

The text notes that because of this exact danger, and because true cholinergic crises are relatively rare in M .G.

patients who are well -educated on their dosing, the edryphonium test is actually considered quite controversial today.

It is.

And it perfectly underscores why the absolute last nursing implication we need to discuss is making sure these patients wear a medical alert bracelet.

If they collapse in public, emergency responders need to know exactly what complex pharmacology they are walking into.

It is a deeply complex chemistry, but when you map the physical properties of the drug directly to the patient's bedside presentation,

the clinical reasoning becomes incredibly clear.

It really does.

And as we wrap up this deep dive into cholinesterase inhibitors, I want to leave you with a final thought to mull over.

We've spent this whole time talking about profound paralysis, high -stakes antidotes, and complex autoimmune pathophysiology.

Heavy topics.

Very heavy.

But underneath all of that, the entire mechanism of these life -changing drugs comes down to one of the simplest processes in nature.

Hydrolysis.

The simple act of a water molecule breaking a chemical bond.

It's amazing when you think about it.

By designing a molecule that just slows down how fast water breaks apart a neurotransmitter, a nurse can literally help a paralyzed patient open their eyes and swallow their food again.

The immense power of a single drop of water engineered perfectly.

An incredibly profound way to view it.

Knowledge applied at the molecular level truly changes lives at the bedside.

Absolutely.

Thank you so much for joining us on this deep dive.

From all of us here, and a special shout out from the Last Minute Lecture Team, we wish you the absolute best of luck on your pharmacology journey.

Keep diving deep, and we'll catch you next time.